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Abstract
Background: Benefits to patients from reduced depression have been shown from monitoring progress with patient-
reported outcome measures (PROMs) in psychological therapy and mental health settings. This approach has not yet
been researched in the United Kingdom for primary care, which is where most people with depression are treated in
the United Kingdom.
Methods: This is a parallel-group cluster randomised trial with 1:1 allocation to intervention and control. Patients who
are age 18+ years, with a new episode of depressive disorder/symptoms, meet the inclusion criteria. Patients with
current depression treatment, comorbid dementia/psychosis/substance misuse/suicidal ideas are excluded. The
intervention includes the Administration of Patient Health Questionnaire (PHQ-9) as a PROM within 2 weeks of diagnosis
and at follow-up 4 weeks later. General practitioners are trained in interpreting scores and asked to take them into
account in their treatment decisions. Patients are given written feedback on scores and suggested treatments. The
primary outcome measure is Depression on the Beck Depression Inventory BDI-II at 12 weeks. Secondary outcomes
include BDI-II at 26 weeks, changes in drug treatments and referrals, social functioning (Work & Social Adjustment Scale)
and quality of life (EQ-5D) at 12 and 26 weeks, service use over 26 weeks (modified Client Services Receipt Inventory) to
calculate NHS costs, and patient satisfaction at 26 weeks (Medical Informant Satisfaction Scale). The sample includes 676
total participants from 113 practices across three centres. Randomisation is achieved by computerised sequence
generation. Blinding is impossible given the nature of the intervention (self-report outcome measures prevent rating
bias). Differences at 12 and 26 weeks between intervention and controls in depression, social functioning and quality of
life are analysed using linear mixed models, adjusted for socio-demographics, baseline depression, anxiety, and
clustering, while including practice as a random effect. Patient satisfaction, quality of life (QALYs) and costs over 26 weeks
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will be compared between arms. Qualitative process analysis includes interviews with 15–20 GP/NPs and 15–20 patients
per arm to reflect trial results and implementation issues, using Normalization Process Theory as a theoretical framework.
Discussion: If PROMs are helpful in improving patient outcomes for depression even to a small extent, then they are
likely to be good value for money, given their low cost. The benefits could be considerable, given that depression is
common, disabling, and costly.
Trial registration: ISRCTN no: 17299295. Registered 1st October 2018.
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Background
Background and rationale {6a}
England, like other countries, has seen big increases in
antidepressants and psychotherapy for depression since
the early 1990s, yet the prevalence of depression has not
declined but actually has increased slightly. One of the
main reasons is a lack of application of evidence-based
treatments to those who would benefit– referred to as
the ‘quality gap’ [1].
NICE guidelines recommend different treatments for
more severe depression than for less severe depression
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[2]. However, general practitioners (GPs), who treat more
than 80% of cases in primary care, are often inaccurate in
their global clinical assessments of depression severity,
and so treatment is not targeted to patients most likely to
benefit [3]. Some patients receive treatment they do not
need (medicalising self-limiting illness and exposing them
to side effects) and others do not get the treatment they
do need, significantly contributing to the ‘quality gap’. A
systematic review concluded that many false diagnoses
occur, as well as missed cases, which could be improved
by reassessment of individuals who might have depression
[4]. As a result, the National Institute for Health and Care
Excellence (NICE) recommends practitioners consider
using depression symptom questionnaires as validated
measures of severity at diagnosis and follow-up, to inform
and evaluate treatment [2].
Questionnaire use was incentivised in the GP contract
from 2006 to 2013. However, since those payments stopped,
most GPs prefer not to use them, saying they intrude in
consultations and undermine their autonomy. Some doubt
their validity, preferring to use their own judgement to assess
severity and response to treatment [5].
A Cochrane review of using PROMs in treating
common mental health disorders (CMHDs) including
depression found some evidence of benefit in
psychotherapy and specialist mental health settings, but
the research was generally of low quality, and hardly any
research had been done in primary care [6]. More
research is therefore required, particularly in UK
primary care, where most patients are treated if they are
treated at all.
Depression is common and costly. The 1-week preva-
lence among adults in the United Kingdom is 11.1%, in-
cluding 3.3% major depression and 7.8% mixed
depression and anxiety [7]. Depression can lead to
chronic disability, poor quality of life, suicide, and high
service use and costs. The King’s Fund estimated that
1.45 million people will have depression in England by
2026, and annual costs for care, social services and lost
employment will be £12.2 billion [8]. If using severity
measures improves the targeting of treatment and out-
comes for depression even to a modest extent, they are
likely to be cost-effective given their low cost, and the
benefits at a population level would be considerable in
public health terms, given the high costs of depression.
Depression symptom questionnaires are an example of
patient-reported outcome measures (PROMs), which
have been promoted to increase patient involvement in
their own care [9], and research shows that patients
value the use of questionnaire severity measures to con-
firm their diagnosis and monitor their progress [5].
Observational research suggests depression questionnaires
can also improve the process of care for patients. Following
NICE guidance, from 2006 to 2013, the GP contract Quality
and Outcomes Framework (QOF) paid GPs to use symptom
questionnaires to assess depression severity at diagnosis of a
new episode. Questionnaire assessments at follow-up were
also rewarded in the QOF from 2009 to 2013. Our previous
observational research conducted in the year following the
introduction of the QOF incentivisation of questionnaire use
found that patients valued the use of them to confirm their
diagnosis and monitor their progress, and some GPs also val-
ued them for monitoring patients [5]. Importantly, treatment
was better targeted. The likelihood of antidepressant
treatment or referral to psychology was found to be
significantly associated with higher questionnaire
scores at diagnosis [10], and at follow-up, decisions to
change treatment were significantly associated with
the lack of improvement in scores [11].
The use of questionnaires was disliked by some GPs
however, who said the questionnaires intruded in
consultations and undermined their autonomy. Some
doubted their validity, preferring to use their own
judgement to assess severity and response to treatment
[5]. In response to these criticisms, NICE commissioned
a review [12] which concluded the evidence was not
strong enough to require their use in QOF depression
indicators. Currently, the QOF rewards reviews 10–35
days after diagnosis, but questionnaires are optional and
not required to receive payments.
However, a recent time series analysis of GP prescribing
data shows the QOF depression indicators were
associated with a subsequent reduction in antidepressant
prescribing for first-ever episodes of depression, which is
in line with NICE guidance not to give antidepressants for
mild depression [13]; therefore, rewarding questionnaire
use should be seriously reconsidered.
Routine outcome monitoring with questionnaire
measures of depression severity takes place in the NHS
Improving Access to Psychological Therapy (IAPT)
psychological treatment services and has been shown to
improve the efficiency of care in that setting [14].
However, only 15% of CMHD patients are treated by the
IAPT programme [15], so more research into the
potential benefits of routine outcome monitoring with
depression symptom severity measures is required in UK
primary care, where most patients are treated, if they are
treated at all.
Systematic reviews of PROMs for depression have
found some evidence of benefit for patients treated in
mental health [16] and psychological therapy settings
[17], but a recent Cochrane review found little research
had been done in primary care [6]. We carried out a
feasibility randomised controlled trial (RCT) of PROMs
for depression in UK primary care [18]. We tested
individual patient and cluster randomisation of 47 adults
with new episodes—22 for the intervention and 25 for
the control—in nine practices. Three PROMs were
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administered following diagnosis and again 10–35 days
later: the Patient Health Questionnaire PHQ-9 [19], the
Distress Thermometer analogue scale [20] and the PSY-
CHLOPS problem profile [21]. Feedback of scores to pa-
tients was left to the practitioners. Mean BDI-II score at
12 weeks was lower among intervention group patients
than controls by 5.8 points (95% CI-11.1, − 0.5), adjusted
for baseline differences and practice [18]. Social func-
tioning scores were not significantly different. At 26
weeks, no significant differences existed in symptoms,
social functioning, quality of life or costs, but the mean
satisfaction score was lower among intervention patients
by 22.0 points (− 40.7,-3.29). Qualitative interviews sug-
gested this was because patients were disappointed when
their GPs did not use PROM scores to inform treatment.
Some GPs were not convinced the PROMs were useful
and wanted more guidance on treatment actions in re-
sponse to the scores [18].
We concluded PROMs might improve outcomes, even
if they do not always inform management, in line with
the findings of a similar trial using the PHQ-9 in the
USA [22]. Patients can feel more involved in their care
and more motivated to adhere to treatment and follow-
up [23, 24]. Primary care patients in Sweden monitored
with the Montgomery-Asberg rating scale were more
likely to adhere to antidepressants, but no improvements
in outcome were observed in that study [25], so findings
are variable and more research needed.
Objectives {7}
The objectives of the study are as follows:
1. To carry out a cluster-randomised, controlled, par-
allel group trial that will compare (i) getting pa-
tients to complete the PHQ-9, which is used as a
patient-reported outcome measure (PROM) in their
consultations with General Medical Practitioners
(GPs) or Nurse Practitioners (NPs) treating them
for depression, with (ii) usual Practitioner care, un-
informed by PHQ-9 scores
2. To motivate and train participating practitioners to
reflect on the best use of the PHQ-9, thereby im-
proving the practitioner’s capability to interpret
symptom scores, taking into account patients’ re-
sponses to open-ended global enquiries, their level
of functioning, past history, and social context, in-
cluding life events and difficulties
3. To provide patients in the intervention arm with
written feedback on their PHQ-9 scores, including a
‘traffic light’ indication of the level of severity of
their depression, a 100-manikin representation of
the proportion of people in the population with that
level of depression, and a brief list of evidence-
based treatments relevant to the level of severity,
which they will be asked to discuss with their GP/
NP
4. To follow up participants for 26 weeks, with
research assessments at 12 and 26 weeks
5. To determine the primary outcome of depressive
symptoms on the Beck Depression Inventory, 2nd
edition (BDI-II), at 12 weeks follow-up
6. To examine secondary outcomes including
depressive symptoms on the BDI-II at 26 weeks,
and social functioning, quality of life, and changes
in drug treatment and referrals, at both 12 and 26
weeks
7. To measure service use and costs over the 26-week
follow-up period and perform cost-effectiveness and
cost-utility analyses based upon the results of the
trial
8. To carry out a qualitative process analysis to
explore participants’ reflections on the conduct of
the trial, and the potential for implementing the use
of PROMs in practice, using. interviews with 15–20
practitioners and 15–20 patients, which will be
carried out using Normalization Process Theory
[26] as a theoretical framework
Trial design {8}
The study is a parallel group, cluster-randomised, con-
trolled, superiority trial, with patients clustered by par-
ticipating practices, and 1:1 allocation of practices to
intervention and control groups. We chose a cluster-
randomised design after a feasibility study that showed
that randomising patients individually within practices
risks contamination between study arms.
Methods/Design
Study setting {9}
The setting is UK primary care, recruiting general
practices around three sites: the University of
Southampton, University of Liverpool, and University
College London (UCL). The full list of sites can be
obtained by email from study administrative assistant
Sophie Johnson at promdep@soton.ac.uk.
Eligibility criteria {10}
The target population is patients aged 18 or more years,
diagnosed by a GP or NP with a new episode of
depression disorder or depressive symptoms. A new
episode means no diagnosis or treatment within the
previous 3 months. The inclusion criteria are adult
patients seen in the practice within the last 2 weeks and
assigned medical record Read codes by GPs or NPs for
new presentations with diagnoses or symptoms of
depression. No upper age limit will be implemented, and
patients will not be excluded for coexisting physical
health problems. Patients will be excluded if they are
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already being treated for depression, or if they have
comorbid dementia, psychosis, or substance misuse (as a
main problem). Patients will also be excluded if they have
significant suicidal thoughts requiring possible urgent
referral to specialist mental health care (see below).
Who will take informed consent? {26a}
Patients identified as potentially eligible in clinic
consultations will be given an information sheet by hand,
together with a reply slip and a Freepost envelope, and
they will be asked to contact the study team if they wish
to take part after they have had time to consider. To avoid
selection bias by the GP/NP, patients presenting with a
new episode of depressive symptoms or disorder will also
be identified through weekly searches of practice medical
records databases for the identification of patients who
were not selected by the GP/NP. Patients identified
through this method will be mailed an information sheet
about the study by the practice and asked to contact the
study team if they wish to take part, or to decline, again
using a reply slip and a Freepost envelope, after they have
had time to consider. If they do not respond, the research
team will have no knowledge of them, maintaining patient
confidentiality, and this will not prejudice their future
treatment. If patients do respond positively to either
approach, a member of the research team will then
contact them, screen them by telephone for any exclusion
criteria, and arrange to see them face to face for a baseline
visit if they are eligible. At the baseline visit, the researcher
will go over the patient information sheet again and seek
formal written consent.
Additional consent provisions for collection and use of
participant data and biological specimens {26b}
This trial does not involve collecting biological specimens
for storage.
Interventions
Intervention description {11a}
The intervention consists of getting patients to
complete the Patient Health Questionnaire (PHQ-9),
which measures depression symptoms, for use as a
patient-reported outcome measure (PROM) in their
consultations with GPs (or Nurse Practitioners, NPs)
treating them for depression. The PHQ-9 will be
completed by participating patients as soon as pos-
sible after diagnosis and then again at a follow-up
consultation 10–35 days after that (this follow-up time
period has been chosen, as it is the interval laid down
for financially incentivised follow-up assessments in
the GP contract quality outcomes framework QOF).
Patients will be given feedback on the meaning of
their symptom score and possible treatment options
to discuss with the practitioner. Practitioners will be
trained in the interpretation of symptom scores in the
context of the patient’s life situation, and they will be
trained in further assessment to inform their treat-
ment decisions.
The PHQ-9 is a nine-question self-report measure of
depression symptoms that takes approximately three mi-
nutes to complete [19]. It asks about the American Psy-
chiatric Association’s Diagnostic and Statistical Manual
(DSM) nine diagnostic symptoms of major depressive
disorder and scores on each symptom range from 0 (not
at all) to 3 (nearly every day). Total scores are cate-
gorised into minimal or no (0–4), mild (5–9), moderate
(10–14) and severe (15–27) depression. It was developed
and originally validated against diagnostic interviews in
the USA and can be downloaded free of charge from
www.depressionprimarycare.org/clinicians/toolkits/mate-
rials/forms/phq9/questionnaire/. Pfizer owns the copy-
right but does not charge for its use in clinical practice
or research [27].
We will provide patients in the intervention arm with
written feedback on their PHQ-9 scores, including a ‘traf-
fic light’ indication of the level of severity of their depres-
sion, a 100 manikin infographic of the proportion of
people in the population with their level of depression and
a brief indication of possible evidence-based treatments
relevant to the level of severity, which they will be asked
to discuss with their GP/NP. PHQ-9 sum scores range
from 0 to 27, with scores of 0–4, 5–9, 10–14 and 15+
representing ‘probable minimal or no depression’, ‘mild’,
‘moderate’ and ‘moderately severe to severe’ depression
symptom levels, respectively. These will be fed back to pa-
tients as one of four severity categories: green (70% of
population on the 100 manikin infographic), yellow (20%),
orange (8%) and red (2%), respectively. The patient feed-
back proformas were derived from similar ones used in
the DEPSCREEN-INFO study of depression screening
with patient-targeted feedback in cardiology [28].
Explanation for the choice of comparators {6b}
Control practice patients will not complete the PHQ-9.
They will receive usual practitioner care for new epi-
sodes of depression and complete research outcome
measures as part of the trial but will not be given feed-
back on the results.
Criteria for discontinuing or modifying allocated
interventions {11b}
No special criteria have been developed for discontinuing
or modifying the allocated interventions.
Strategies to improve adherence to interventions {11c}
Many GPs in UK practice are familiar with the PHQ-9,
as it was the most frequently used PROM in practices in
the period (2006–13) during which the use of depression
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symptom questionnaires was incentivised by the QOF
[10]. However, some GPs doubt the validity of the PHQ-
9, preferring to use their own judgement to assess sever-
ity and response to treatment [5]. The PHQ-9 meets
minimum standards for a PROM [29] in terms of estab-
lished validity in UK primary care [30] and sensitivity to
change in response to treatment, at least at the group
level [31]. It was recommended for use by the PROM
Research Group at the Oxford Department of Public
Health as having evidence to support its use and being
broadly acceptable [32].
The severity categories of the PHQ-9 can be criticised,
as a score of 5–9 (‘mild depression’) is found in approxi-
mately 20% of the population, but is not usually associ-
ated with significantly impaired functioning, so labelling
people scoring 5–9 as having depression may be coun-
terproductive, in that treatment is not usually indicated,
and the label itself may make patients feel worse about
themselves. The cut-off of a score of 10 for moderate de-
pression, as the threshold for offering treatment, has also
been questioned, and studies have suggested a score of
12 may be a more valid threshold [10]. The PHQ-9
tends to put more people in the ‘moderate depression’
category than other PROMs such as the Hospital Anx-
iety and Depression Scale for example [10, 33].
In any case, an initial high PHQ-9 score by itself,
whether above 10 or above 12, does not suffice to indi-
cate the need for antidepressant drug treatment or refer-
ral for psychological therapy because patients vary
greatly in their propensity to acknowledge symptoms
when asked. Recent qualitative research led by co-
applicants Dowrick and Lewis suggests that the PHQ-9
is not exhaustive in its list of symptoms and not all pa-
tients find it straightforward to complete, so it may miss
symptoms that are meaningful to patients (e.g., changes
in libido, social withdrawal, interpersonal difficulties),
and underestimate their intensity [34]. Some patients
consciously underreport their symptoms to try to reduce
them through positive affirmations, while others overre-
port them to emphasise they want help. Consequently,
as many as half of patients rated with the PHQ-9 may
have a mismatch with how they describe their overall
condition at baseline, as well as their progress over time,
when asked global, open-ended questions [34].
Symptom scores are therefore quite individual, and
the baseline level has to be interpreted in light of the
impact of the symptoms on the person’s functioning at
home, at work and in relationships. The recent
qualitative research suggests that the PHQ-9 should not
be used as a standalone tool but should preferably be
used in conjunction with an open-ended enquiry such
as ‘how are you feeling in yourself?’ [34], as a better
measure of the person’s unique ongoing experience of
their depression. Additionally, within-person changes in
individuals’ PHQ-9 scores between the first and second
consultation are only limited indicators of whether pa-
tients are improving, not improving or getting worse
and therefore need to be supplemented with a global en-
quiry such as ‘how are you feeling in comparison to
when I last saw you?’ along with an update on their life
circumstances [34]. Where mismatches exist between
changes in patient scores and global ratings of change,
practitioners need to take particular care when inter-
preting the results of the PHQ-9.
Our feasibility study suggested that GPs’ discussion of
the PHQ-9 scores with patients and their use of them
to inform treatment were suboptimal, affecting both
their own perception of the measure, and patients’ sat-
isfaction with the care they received [18]. To change
practitioner behaviour in the proposed trial, we will im-
plement 2 hours of structured training. By triangulating
our qualitative feasibility findings with behavioural the-
ory [35], we determined the need for the training to
focus primarily on GP’s reflective motivation (e.g., be-
liefs about the usefulness of PROMS) and psychological
capability (e.g., knowledge and understanding to apply
PROMS effectively). These constructs are drawn from
the ‘COM-B’ system of behaviour (referring to Capabil-
ity, Opportunity, Motivation and Behaviour) [35]. The
COM-B system is used widely in behaviour change re-
search and focuses on necessary antecedents for volun-
tary behaviour to occur. Participating GPs will
therefore be given up to 2 hours of training either face
to face on their practice premises or on-line, including
written material beforehand (informed by the NICE
guidelines), a PowerPoint presentation, case vignettes,
and questions for them to answer to show they have
understood the training.
To get GPs/NPs to reflect on the value of the use
of the measure, the training will focus on evidence
that patients do value using PROMs and can benefit
from being more involved in their own care even if
the scores do not alter treatment decisions. We will
address GP/NP concerns around the validity of the
PHQ-9 by acknowledging individual differences in pa-
tient response set, and advising them to combine
more global open-ended questions with the question-
naire measure. GPs will thus be trained in interpret-
ing individual PHQ-9 scores along with how to ask
open-ended questions and explore the patient’s life
context; these GPs will be asked to take this informa-
tion into account in their treatment decisions.
Relevant concomitant care permitted or prohibited during
the trial {11d}
Practitioners in both the intervention and control groups
will be advised that best practice in treating depression is
not to start treatment at the consultation at which
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symptoms of a new episode are presented by the patient,
unless they think it is absolutely indicated in their clinical
judgment. This is because a significant proportion of
patients will improve without treatment within 2–3 weeks,
having had their problems acknowledged and having
received general advice about the nature and course of
depression. We are interested in this study with the use of
the PHQ-9 when deciding on initial treatment, as well as
follow-up monitoring, so we prefer treatment not be
started before the baseline assessment in both groups and
before the first PHQ-9 questionnaire has been adminis-
tered by the researcher in the intervention group. In the
feasibility study, this baseline assessment was carried out
on average 10 days (range 1–38 days) from receiving the
patient’s reply slip, so completion of this baseline assess-
ment within 2 weeks of the patient’s first presentation
should be possible in most cases.
However, patients recruited either opportunistically or
via the weekly searches possibly will have been started
on treatment at the consultation, when they first
presented with a new episode, if treatment cannot be
postponed in the judgement of the treating practitioner.
We will record whether treatment has already started at
the baseline assessment.
Provisions for post-trial care {30}
No harm or compensation is anticipated for trial
participation.
Outcomes {12}
The primary outcome is the symptom score on the Beck
Depression Inventory second edition BDI-II [36] for the
current level of depression at the 12-week follow-up. Sec-
ondary outcomes are the BDI-II score at 26 weeks, anxiety
on the GAD-7 measure of generalised anxiety disorder
[37], and scores at both 12 and 26weeks on the Work &
Social Adjustment Scale [38] for social functioning, the
EuroQol 5-item 5-level (EQ-5D) questionnaire for quality
of life [39] and the number and amounts of drug treat-
ments and referrals for depression over the 26 weeks of
total follow-up, as determined using a modified version of
the Client Service Receipt Inventory [40] to calculate NHS
costs. In addition, a modified version of the Medical In-
formant Satisfaction Scale MISS [41] will be administered
at 26 weeks to measure patient satisfaction over the
follow-up period.
The Beck Depression Inventory, second edition BDI-II
is a 21-item self-report instrument that uses DSM-IV
criteria [36]. It has been established as a valid and reli-
able instrument for depression screening in the general
population [36, 42] and is widely used in depression tri-
als. It takes approximately 5 minutes to complete. Each
item is scored from 0 to 3, and a total score of 0–13 is
considered minimal range, 14–19 is mild, 20–28 is mod-
erate, and 29–63 is severe.
The Work and Social Adjustment Scale (WASA)
assesses problems in functioning with work, home
management, social leisure activities, private leisure
activities and family and relationships, all on 0 to 8
scales [38]. It has been shown to be a sensitive, reliable
and valid measure of impaired functioning and is used
routinely in IAPT psychological therapy settings as well
as in research studies in a variety of settings.
The EuroQol-5D (EQ-5D)-5 L measure of health-related
quality of life [39] is the measure favoured by NICE in de-
termining cost-effectiveness when developing its clinical
guidelines. The EQ-5D includes five dimensions: mobility,
self-care, usual activities, pain/discomfort, and anxiety/de-
pression, each scored on five levels. Health states are con-
verted into a single summary index by applying weights to
each level in each dimension derived from the valuation of
EQ-5D health states in adult general population samples
[43]. The EQ-5D measure of patient utility will be used to
determine changes in quality adjusted life years (QALYs)
for the health economics evaluation.
Costs will be calculated from responses to the Client
Service Receipt Inventory CSRI [40], modified specifically
for the study. A review of participating patients’ digital
medical records will also be carried out by practice staff
after the 26-week follow-up, to augment questionnaire
measurement of health and social service resource use
using the modified CSRI.
The 29-item ‘Medical Interview Satisfaction Scale’
(MISS-29) was developed in the USA to assess patient
satisfaction with individual doctor-patient consultations
and has been shown to be valid and reliable in UK pri-
mary care [41]. We will adapt it to rate patient satisfac-
tion at the 26-week follow-up, asking patients to look
back over their consultations with GPs/NPs over the en-
tire 26-week period.
Participant timeline {13}
Sample size {14}
We need a sample large enough to detect a difference
between arms at follow-up of the minimal clinically im-
portant score (MCID) on the primary outcome: the Beck
Depression Inventory 2nd edition (BDI-II).
Button et al. [44] used data collected from three
randomised controlled trials (n = 1039) for the management
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of depression and compared improvement on a ‘global
rating of change’ question with changes in BDI-II scores.
They used general linear modelling to explore baseline de-
pendency, assessing whether MCID is best measured in ab-
solute terms (i.e., difference) or as percentage reduction in
scores from baseline (i.e., ratio). The modelling indicated
that MCID is best measured on a ratio scale as a percentage
reduction of score, and an MCID of a 17.5% reduction from
baseline was identified from receiver operator characteristics
analyses as the optimal threshold above which individuals
reported feeling ‘better’ [44].
In the PROMDEP feasibility trial, we found the mean
BDI-II score at baseline was 24.0, and the standard devi-
ation (SD) was 10.0 [18]. At the 12-week follow-up,
based on the results of the feasibility study, we anticipate
a mean of 14.0 in the intervention group and 17.0 in the
control group. This gives a mean difference of 3.0 on the
BDI-II, which is an effect size of 0.3 SDs and agrees with
the findings of Knaup et al’s systematic review for the
expected effects of combined practitioner and patient
feedback of PROMs [16]. The difference of 3.0 points is
17.6% of the control group’s score of 17.0 at 12 weeks,
and therefore, this score is just above the MCID for the
BDI-II [44]. The anticipated potential benefit would
therefore be small but clinically significant.
We aim to recruit a mean of six patients per practice.
We assume an intra-cluster correlation coefficient (ICC)
of 0.03 (from the feasibility study). At the level of 5% sig-
nificance, to have 90% power to detect a difference be-
tween 14.0 and 17.0 on the BDI-II we need 235 patients
analysed per group. Given a cluster size of six, the clus-
ter design effect will be 1.15, meaning we need 270 per
group. We assume a 20% loss to follow-up at 12 weeks,
so the total sample size needed will be 270 × 2/0.8, which
is a total of 676 patients recruited from 113 practices
across the three recruitment centres (around Southamp-
ton, UCL and Liverpool).
Recruitment {15}
Method 1 Where possible, patients who are seen with a
new episode of depressive symptoms or disorder will be
recruited opportunistically during consultations by
participating GPs and NPs in both arms of the study.
Patients identified through this method will be given the
information sheet by hand, along with a reply slip and a
Freepost envelope, and will be asked to contact the
study team if they wish to take part.
Method 2 Method 1 may be subject to selection bias by
the GP/NP; therefore, to guard against this, we will
identify all patients presenting with a new episode of
depressive symptoms or disorder through weekly searches
of practice medical records databases to find patients who
were not selected for approach by the GP/NP. In the
feasibility trial, both methods were used and 79% of patients
were recruited in consultations opportunistically, and 21%
through the weekly database searches, but the method used
varied by practice, and some practices recruited the majority
of patients through the weekly searches.
Our experience gained while recruiting people with
depression for previous studies has shown that
approximately 120 Read codes are used by GP/NPs,
including diagnostic codes (e.g., major depressive disorder)
and symptom codes (e.g., low mood). Practices will use the
full list for searching their databases weekly. Patients
identified through this method will be mailed an information
sheet about the study by the practice and asked to contact
the study team if they wish to take part, or to decline, using a
reply slip and a Freepost envelope. If they do not respond,
the research team will have no knowledge of them,
maintaining patient confidentiality.
Assignment of interventions: allocation
Sequence generation {16a}
Randomisation will be by computerised sequence
generation, and minimisation with a random element
using three factors to avoid imbalance between the two
arms: practice size (large vs small), location (urban/
suburban vs rural), and centre (Southampton vs
Liverpool vs UCL).
Concealment mechanism {16b}
Randomisation is being carried out by the NIHR Clinical
Trials Unit (CTU), Southampton, remote from the
research teams recruiting the practices. Notification of
allocation is by researcher telephone call to the Unit.
Implementation {16c}
The allocation sequence is generated by the CTU, the
research teams enrol the participant practices, and the
CTU assigns participant practices to the intervention or
control arms.
Assignment of interventions: blinding
Who will be blinded {17a}
Blinding of both patients and practitioners in the
intervention arm is impossible given the nature of the
intervention. Self-report outcome measures are therefore
being used to prevent observer rating bias by research
team members aware of the patient’s assigned trial arm.
The statisticians and health economists analysing the
data are being kept blind to the allocation.
Procedure for unblinding if needed {17b}
The statisticians and health economists analysing the
data will be unblinded to allocation only after all the
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data have been collected, entered into the database and
cleaned.
Data collection and management
Plans for assessment and collection of outcomes {18a}
Data collection will be through face-to-face meetings,
but on-line, postal or telephone follow-up will be offered
if the researcher is unable to arrange to meet patients
face-to-face. Baseline and follow-up assessments will
take place either at the patient’s general practice or at
their home if they prefer.
Research staff will enter participant data onto study
laptop computers and upload them to the study database
on return to the University. Study administrative staff will
check the data for missing or anomalous values. Data
queries will be raised with the recruiting site by the
research team.
Qualitative interviews also will be carried out with 15–20
practitioners and 15–20 patients in each arm (total 30–40
of each) to explore their reflections on the conduct of the
trial and the potential for implementing the use of PROMs
in practice, using NPT as a framework for the initial
interview schedules and qualitative analyses. Practitioner/
patient dyads will be interviewed as soon as possible after
patient assessments at follow-up consultations to explore
patient and practitioner recall of interactions within the
consultation and to identify variations in the use of PROMs
and in usual practitioner care.
Plans to promote participant retention and complete
follow-up {18b}
Participants will receive a £10 high street shopping
voucher at both the 12- and 26-week follow-ups to
thank them for their participation in the study. Partici-
pants will also receive a £10 high street shopping vou-
cher for taking part in a qualitative interview.
Three attempts will be made to arrange to assess patients
face-to-face, by post, or on-line within 4 weeks of the assess-
ment becoming due. Following this further attempts to ob-
tain at least the primary outcome (BDI-II score) and quality
of life measure (EQ-5D) over the telephone will be made, if
the participant is unable to complete assessment instruments
face to face, by post, or on-line.
Patient and practitioner participants will be free to
withdraw consent at any time without providing a
reason. When withdrawn, patient participants will
continue to receive standard clinical care from their
practitioner. Follow-up data will continue to be collected
(unless the participant has specifically stated that they
do not want this to happen).
Data management {19}
Participant data will be entered on laptop computers on
site and then transferred to electronic databases and
stored at the University of Southampton. Data stored
will be checked for missing or unusual values (range
checks) and checked for consistency within participants
over time. Any suspect data will be returned to the
researcher or practice in the form of data queries. The
CI will be responsible for ensuring the accuracy,
completeness and timeliness of the data entered.
Confidentiality {27}
Participant data will be pseudo-anonymised by assigning
each participant a participant identifier code which will
be used to identify the participant during the study and
for any participant-specific clarification between the
University of Southampton as Sponsor, and the partici-
pating general practices.
The Informed Consent Form will specify the
participant data to be collected, how it will be managed,
and how it might be shared, including the handling of
all Patient Identifiable Data (PID) and sensitive PID in
adherence to relevant data protection law. Only trained
personnel with specific roles assigned will be granted
access to the electronic patient data.
Data will be retained at the University of Southampton in
accordance with the General Data Protection Regulation
(2018). The participants’ medical records and other relevant
data may also be reviewed by appropriate qualified personnel
independent from the trial team, appointed to audit the
study, including representatives of the Competent Authority.
Details will remain confidential and participants’ names will
not be recorded outside the University.
Plans for collection, laboratory evaluation and storage of
biological specimens for genetic or molecular analysis in
this trial/future use {33}
No biological specimens will be collected.
Statistical methods
Statistical methods for primary and secondary outcomes {20a}
A full and detailed statistical analysis plan will be
developed prior to the final analysis of the study. The
main features of the statistical analysis plan are as follows:
The primary outcome, that is, the differences at 12
weeks between intervention and controls in depression
as measured by the BDI-II, will be analysed using a lin-
ear mixed model, adjusting for socio-demographics,
baseline depression, anxiety, and clustering, including
practice as a random effect. The model will use all the
observed data and makes the assumption that missing
BDI-II scores are missing completely at random.
Analysis of secondary outcomes, BDI-II at 26 weeks,
social functioning, patient satisfaction and quality of life
score, will also be conducted using linear regression for
continuous outcomes and logistic regression for dichot-
omous outcomes, again adjusting for socio-demographics,
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baseline depression, anxiety, and clustering, including
practice as a random effect.
A health economic evaluation will be undertaken from a
National Health Service and Personal Social Service
perspective, with a sensitivity analysis from a societal
perspective. The outcome will be expressed as incremental
cost per point improvement in the BDI-II clinical outcome,
and incremental cost per quality adjusted life year (QALY)
gained (cost utility analysis). All items will be costed using
appropriate data (e.g., PSSRU NHS and social care refer-
ence costs [45]), with informal care costed at minimum
wage level. The primary analysis will be at 26 weeks. Per-
sonal costs will include patient and carer time off work,
personal expenses and travel.
A generalised linear mix model will be used to
estimate the differences in costs and QALYs (using the
EQ-5D to calculate patient utilities), adjusting for base-
line characteristics including depression history, quality
of life and sociodemographic factors. Where appropriate,
we will estimate incremental cost-effectiveness ratios
(ICERs). We will estimate mean values and 95% percen-
tiles using non-parametric bootstrapping, and use these
to produce cost-effectiveness acceptability curves
(CEACs). Major assumptions in the costing and QALYs
analysis will be tested through sensitivity analyses. Mod-
elling of the likely benefit, if any, of using PROMs in
practice will include making assumptions about the extra
time which would have to be taken for GPs/NPs to ad-
minister the initial PROM (rather than the researcher)
in the non-trial situation, together with any payments
that might have to be made to practices, e.g., through
the QOF, to incentivise the use of PROMs.
Interim analyses {21b}
No interim analyses are planned. Full details of the
analyses to be undertaken will be set out in a statistical
analysis plan, to be approved by the independent trial
steering committee (TSC).
Methods for additional analyses (e.g., subgroup analyses)
{20b}
No subgroup analyses are planned. Any post-hoc ana-
lyses will be exploratory only.
A qualitative process evaluation will also be
conducted. Process evaluation is an important tool for
understanding both the dynamics and the outcomes of
clinical trials, and Normalization Process Theory NPT
[26] is a conceptual toolkit developed for this purpose
[46]. NPT focuses on understanding the mechanisms
that promote and the factors that inhibit, sense-making,
participation, action and monitoring by participants in
implementation processes.
The objectives of the process evaluation in the trial are to
identify, characterise and explain the perspectives of patient
and practitioner participants on the conduct of the trial and
to construct a taxonomy of factors affecting both the
conduct of the trial and the potential for normalisation of
the use of PROMs in everyday practice, outside of the trial
situation. The analysis will enable the construction of an
implementation framework of barriers and facilitators
(patient and health system factors) that need to be taken
into account in the use of PROMs in primary care practice.
The qualitative interviews will be transcribed and
emerging themes identified through inductive analysis
using the constant comparative method [47]. We will
draw on insights from the wide range of studies that have
employed NPT, giving a basic structure to the topic guide
to be written in advance of the interviews. However, we
will also work prospectively and inductively to ensure that
we identify, characterise and understand (i) disconfirming
evidence and deviant cases, and (ii) processes that are not
accounted for within NPT.
Methods in analysis to handle protocol non-adherence and
any statistical methods to handle missing data {20c}
We will examine the structure and pattern of missing data
and, if appropriate, will present a sensitivity analysis based
on data imputed using a multiple imputation model. Data
will be analysed on an intention-to-treat basis.
Plans to give access to the full protocol, participant level-
data and statistical code {31c}
No plans have been made to share data publicly at
present. The trial dissemination group, whose purpose is
to oversee the planned outputs from the trial and agree
on data sharing arrangements, comprises the CI Tony
Kendrick (TK) in Southampton and one co-applicant
from each of the other two centres—Liverpool (Chris
Dowrick (CD)) and London (Glyn Lewis (GLew)).
Oversight and monitoring
Composition of the coordinating centre and trial steering
committee {5d}
TK, CD and GLew lead weekly local study team meetings
at Southampton, Liverpool and UCL, respectively, and the
overall PROMDEP Trial Management Group (TMG)
meets every month by teleconferencing to review progress
and give advice on the conduct and management of the
study. The TMG includes representatives with expertise
in general practice, psychiatry, psychology, sociology,
statistics and health economics and is supported by two
Patient and Public Involvement (PPI) contributors and
CTU staff involved in the day-to-day running of the trial.
An independent Trial Steering Committee (TSC) has been
set up to oversee trial conduct, consisting of an academic
psychologist (chair), academic psychiatrist, statistician,
health economist and patient representative.
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Composition of the data monitoring committee, its role and
reporting structure {21a}
An Independent Data Monitoring Committee (IDMC) has
also been set up, consisting of an academic general
practitioner (chair), statistician and academic psychologist.
Although no pre-specified stopping rules have been estab-
lished, the IDMC will review outcome and safety data
regularly during the trial to advise the TSC on continu-
ation of the trial.
Adverse event reporting and harms {22}
Any adverse events reported by patients or practitioners will
be brought to the attention of the Trial Coordinator and
Chief Investigator (CI) or in the absence of the CI, one of the
Principal Investigators (PIs). The CI or PI will decide
whether or not to inform Sponsor or the Research Ethics
Committee (REC), TSC or IDMC. The report will include
the event, when the information was reported, assessment of
seriousness and likely relationship to participation in the
trial. All serious adverse events (SAEs) will be reported to the
Chief Investigator and the Trial Coordinator within 24 h of
the local site becoming aware of the event. We will record
the nature of the event, date of onset, severity, corrective
therapies given, outcome, causality (i.e., unrelated, unlikely,
possible, probably, definitely) and expectedness. The Chief
Investigator will assign the causality and expectedness of the
event and the term should be in accordance with the latest
version of MedDRA and grades given in accordance with the
NCI CTCAE v4.03. Additional information will be provided
as soon as possible if the event has not resolved at the time
of reporting.
The Chief Investigator or Programme Manager will
notify the REC of related and unexpected SAEs occurring
during the study according to the following timelines: fatal
and life-threatening within 7 days of notification and non-
life threatening within 15 days. Adverse events will also be
reported to the IDMC, who will advise the TSC about
continuation and whether interim analyses are needed.
The TSC will work with the IDMC and be kept informed
by the CI, PI, or Trial Coordinator. If an extension is re-
quested, the TSC will be responsible for looking into the
details as to why this is needed and to give an opinion that
will inform the funder (NIHR) and the sponsor (University
of Southampton).
Frequency and plans for auditing trial conduct {23}
No specific audits are planned. However, participant trial
records, medical records and other relevant data may be
reviewed by appropriate qualified personnel, including
representatives of the Health Research Authority, who are
independent from the trial team and appointed to audit the
study. Details will remain confidential, and participants’
names will not be recorded outside the University.
Plans for communicating important protocol amendments to
relevant parties (e.g., trial participants, ethical committees) {25}
Proposed important protocol modifications (e.g., changes
to eligibility criteria, outcomes and analyses) will be
discussed with the co-investigators before seeking ap-
proval from the Health Research Authority and REC, and
subsequently, these modifications will be communicated
to the trial registry and to any journals where publication
is underway).
Dissemination plans {31a}
The results will be disseminated to participating
practices in summary form as well as to academic
audiences via publication in peer-reviewed journals and
general practice trade publications. We also will publi-
cise our findings through existing primary care networks
and patient groups. Summary trial results will be avail-
able on the websites of the participating Universities.
Discussion
If PROMs are helpful in improving patient outcomes for
depression even to a small extent, then they are likely to
be good value for money, given their low cost. The
benefits could be considerable, given that depression is
common, disabling and costly.
Trial status
This paper is based on Version 1.4 of the protocol, dated 4
January 2019 and approved by the REC and HRA on 30
January 2019. Recruitment began on 1 December 2018, and
the approximate date when recruitment will be completed is
31 January 2021. The end of the study is defined as the date
of the last follow-up visit of the last patient (expected to
occur 6months after the last patient is recruited).
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